trial

Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression

NCTId NCT02661789
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 63 (actual)
Sponsored by Gitte Moos Knudsen
Primary completion 2012-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
63 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-01
Primary completion
2012-12
Eligibility
FEMALE · 18 Years · 40 Years

Interventions & indications

Drugs
Goserelin 3.6 mg implant

Sponsors

Gitte Moos KnudsenLead Sponsor
Center for Integrated Molecular Brain Imaging, Copenhagen, DenmakCollaborator
Rigshospitalet, DenmarkCollaborator
Glostrup University Hospital, CopenhagenCollaborator
Danish Multiple Sclerosis Center RigshospitaletCollaborator

Investigators

1
Vibe G Frokjaer, MD, PhdPrincipal Investigator

Sites

1 total
Copenhagen, Denmark

Facts & assertions

4 sourced
Enrollment
63
Phase
NA
Primary Completion Date
2012-12
Status
COMPLETED
relationships
The graph out of here
drug
Goserelin 3.6 mg implant
drug
lead_sponsor
Gitte Moos Knudsen
company
collaborator
Center for Integrated Molecular Brain Imaging, Copenhagen, Denmak
company
Rigshospitalet, Denmark
company
indication
Major Depressive Disorder
indication
Neurodegeneration
indication
Postpartum Psychosis
indication
investigator
Vibe G Frokjaer, MD, Phd
person